GLP-1RA reduces risk of CV events associated with overweight and obesity
Results with novel FXI inhibitor in AF set the stage for phase 3 trials
Christian Ruff, MD
An option for lowering BP beyond prescribing an additional pill
Florian Rader, MD
GLP-1RA for CVD risk reduction in obesity and overweight - Clinical implications
Michael Lincoff, MD
Deepak Gupta, MD
Loading...
We’re glad to see you’re enjoying PACE-CME… but how about a more personalized experience?
Press cancel to remain on PACE-CME. Press the link below or the continue button to keep going.